Amber List

ARQTArcutis Biotherapeutics, Inc.

Healthcare · Biotechnology · mid-cap ($3.2B)
-20.2%
from rolling 252-day high of $31.77 set 2025-12-08 · 255d ago
Current
$25.35
Decline depth
-20.2%
Decline σ
6.2σ
TFC
3/5 bearish
Rolling 252-day high Up day Down day Last 90 trading days · data from Alpaca

Since it joined the list

$ARQT landed on the list 2026-03-02, down 22.1% from its 52-week high that day — now down -20.2%.

It has clawed back 1.0 percentage points off that level. It bottomed 38.6% below that high along the way.

Decline from the 52-week high as it stood on 2026-03-02 (fixed anchor) → today. Split-adjusted, Alpaca. Observed history, not a forecast.

Structural break signals

ARQT qualifies for the Amber List on decline depth.

Decline depth
-20.2%
From rolling 252-day high of $31.77, 255d ago. Past the 20% Watch threshold.
Time-frame continuity
3/5 bearish
Latest bar across daily/weekly/monthly/quarterly/yearly time frames. A bar counts as bearish when it's a 2-Down or a red 3. Past the 3/5 Watch threshold.
Decline sigma
6.2σ
Drop from local high over the last 20 bars, expressed in units of the stock's typical daily volatility (2.59% per day). Past the ≥6σ Amber threshold.

The structural read

What price action says about ARQT.

ARQT qualifies for the Amber List on decline depth — down -20.2% from its rolling 252-day high.

Cross-confirmation: also showing 3/5 bearish time frames.

Cross-confirmation: decline sigma also reads 6.2σ over 20 bars.

Upstream TFC read: bearish alignment, current phase daily. Last bar types — daily 2D (red), weekly 3 (red), monthly 2D (red).

Earnings on file: 2026-08-05. Tiering is unaffected by earnings dates — listings reflect price structure only.

Questions about ARQT

What people ask.

Why is ARQT on Broken Stocks?

ARQT qualifies for the Amber List on decline depth. It is down -20.2% from its rolling 252-day high of $31.77, set on 2025-12-08 — 255d ago.

Is ARQT a falling knife?

No. The falling-knife label usually implies a steep, severe drop — typically 30% or more from a fresh high. ARQT is down -20.2% from its 52-week high, which qualifies for the Watch tier but is shallower than the falling-knife pattern. It's an early-stage decline rather than a sharp breakdown.

Is ARQT a buy?

Broken Stocks does not issue buy or sell recommendations. The list is a rules-based technical warning system. It tracks structural decline depth and recency — not company quality, management, fundamentals, or news. Always do your own research and consult a licensed advisor.

Where is ARQT trading inside its 52-week range?

At $25.35, ARQT sits 61.5% of the way from its 52-week low ($15.10) to its 52-week high ($31.77). A reading below 25% indicates price is hugging the bottom of the range; above 75%, the top.

How fast has ARQT been declining?

The current 20.2% decline accrued over 255d, which annualizes to roughly -28.9% per year. Annualized pace is a sanity check — a 30% decline in three months is a different signal than a 30% decline over two years.

How does ARQT compare to its sector?

There are 143 other Healthcare tickers on Broken Stocks: 70 Red, 34 Amber, 39 Watch, with 50 showing recovering structural signals. Median sector decline is -36.1% — ARQT's decline is shallower than the sector median.

Does ARQT's earnings date affect its tier?

No. Tiering is decided purely by decline depth and recency of the rolling-high date. The earnings date on file (2026-08-05) is shown for reference only — listings can move tier between scans based on closing prices, regardless of fundamentals or news events.